Animal models for chronobioticsARMSTRONG, S. M.European journal of medicinal chemistry. 1995, Vol 30, pp 653s-660s, issn 0223-5234, SUPConference Paper

Multidrug resistance to anticancer agents: suitable targets for modulation?BARRAND, M. A.European journal of medicinal chemistry. 1995, Vol 30, pp 455s-466s, issn 0223-5234, SUPConference Paper

Pharmacology of retinoids in the skin: in vitro and in vivo assaysSHROOT, B; MICHEL, S.European journal of medicinal chemistry. 1995, Vol 30, pp 487s-503s, issn 0223-5234, SUPConference Paper

The design of therapeutically effective 5-lipoxygenase inhibitorsWALKER, E. R. H.European journal of medicinal chemistry. 1995, Vol 30, pp 399s-416s, issn 0223-5234, SUPConference Paper

Endothelium-derived relaxing factorsVANHOUTTE, P.-M.European journal of medicinal chemistry. 1995, Vol 30, pp 361s-370s, issn 0223-5234, SUPConference Paper

The molecular mechanism of amyloid formation in Alzheimer's diseaseKANSBURY, P. T.European journal of medicinal chemistry. 1995, Vol 30, pp 621s-633s, issn 0223-5234, SUPConference Paper

Galanin receptor ligands as potential therapeutic agents in depression and neurodegenerationBARTFAI, T; LANGEL, Ü.European journal of medicinal chemistry. 1995, Vol 30, pp 163s-174s, issn 0223-5234, SUPConference Paper

Melatonin analogues from pharmacology to clinical applicationGUARDIOLA-LEMAITRE, B; DELAGRANGE, P.European journal of medicinal chemistry. 1995, Vol 30, pp 643s-651s, issn 0223-5234, SUPConference Paper

The role of melatoninergic agonists in the clinicDEFRANCE, R; MOCAER, E.European journal of medicinal chemistry. 1995, Vol 30, pp 231s-241s, issn 0223-5234, SUPConference Paper

Treatment development strategies for Alzheimer's diseaseWÜLFERT, E.European journal of medicinal chemistry. 1995, Vol 30, pp 147s-162s, issn 0223-5234, SUPConference Paper

New potent and selective non-peptide antagonists of neurotensin receptorsMAFFRAND, J.-P; GULLY, D; BOIDEGRAIN, R et al.European journal of medicinal chemistry. 1995, Vol 30, pp 551s-573s, issn 0223-5234, SUPConference Paper

Improvement of antisense oligonucleotides by synthetic modificationsDE MESMAEKER, A; WALDNER, A; FRITSCH, V et al.European journal of medicinal chemistry. 1995, Vol 30, pp 479s-484s, issn 0223-5234, SUPConference Paper

Protein three-dimensional structure and drug design: some examples from intracellular components of the signal transduction pathwayTIMM, D; GURUPRASAD, L; BAX, B et al.European journal of medicinal chemistry. 1995, Vol 30, pp 605s-620s, issn 0223-5234, SUPConference Paper

SR 46559A, an atypical muscarinic compound with no cholinergic syndrome: chemical approach and pharmacological profileBOIGEGRAIN, R; KAN, J.-P; OLLIERO, D et al.European journal of medicinal chemistry. 1995, Vol 30, pp 175s-185s, issn 0223-5234, SUPConference Paper

The development of potent and highly selective thrombin inhibitorsHILPERT, K; ACKERMANN, J; BANNER, D. W et al.European journal of medicinal chemistry. 1995, Vol 30, pp 131s-138s, issn 0223-5234, SUPConference Paper

Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by aspirin and other nonsteroidal antiinflammatory drugsSMITH, W. L; LECOMTE, M; LANEUVILLE, O et al.LECOMTE, M; European journal of medicinal chemistry. 1995, Vol 30, pp 417s-427s, issn 0223-5234, SUPConference Paper

Structure-activity relationships of melatonin analoguesCAIGNARD, D.-H; LESIEUR, D; DEPREUX, P et al.European journal of medicinal chemistry. 1995, Vol 30, pp 637s-642s, issn 0223-5234, SUPConference Paper

Structure-based design of CD4 analoguesJAMESON, B; MCDONNEL, J; WASSEL, R et al.European journal of medicinal chemistry. 1995, Vol 30, pp 215s-228s, issn 0223-5234, SUPConference Paper

Synthesis and structure-activity relationships in perhydroisoindole substance P antagonistsPEYRONEL, J.-F; TABART, M; ACHARD, D et al.European journal of medicinal chemistry. 1995, Vol 30, pp 575s-585s, issn 0223-5234, SUPConference Paper

The thrombin receptor: activation and coupling to mitogenic signaling systemsVAN OBBERGHEN-SCHILLING, E; CHAMBARD, J.-C; VOURET-CRAVIARI, V et al.European journal of medicinal chemistry. 1995, Vol 30, pp 117s-130s, issn 0223-5234, SUPConference Paper

Uroselective α₁-adrenoceptor antagonists for the treatment of benign prostatic hypertrophyGEORGE, P; BORG, F; O'CONNOR, S et al.European journal of medicinal chemistry. 1995, Vol 30, pp 299s-310s, issn 0223-5234, SUPConference Paper

3D models of hormone receptors: experimental validationHIBERT, M; HOFLACK, J; TRUMPP-KALLMEYER, S et al.European journal of medicinal chemistry. 1995, Vol 30, pp 189s-199s, issn 0223-5234, SUPConference Paper

Design of highly potent nonpeptidic fibrinogen receptor antagonistsHIMMELSBACH, F; AUSTEL, V; GUTH, B et al.European journal of medicinal chemistry. 1995, Vol 30, pp 243s-254s, issn 0223-5234, SUPConference Paper

Aldose reductase from pig lensTETE-FAVIER, F; BARTH, P; MITCHLER, A et al.European journal of medicinal chemistry. 1995, Vol 30, pp 589s-603s, issn 0223-5234, SUPConference Paper

Rational drug design based on target structure analogies and molecular biology studiesROQUES, B. P; GARBAY, C; CORNILLE, F et al.European journal of medicinal chemistry. 1995, Vol 30, pp 51s-66s, issn 0223-5234, SUPConference Paper